5-Amino-1MQ
Investigational small molecule; Not a peptide
Brief Overview: 5-Amino-1MQ is included because peptide clinics and metabolic-stacking discussions often mention it, but chemically it is not a peptide. It is usually discussed as an NNMT inhibitor related to fat-cell metabolism and NAD salvage pathways. Evidence lens: Most claims are preclinical or early-stage. The main editorial note is categorization: do not present it as a peptide, and do not treat animal metabolic findings as proven human fat-loss outcomes. How to read this: if you're new, ask why it is in a peptide guide at all; The answer is practical marketplace overlap, not chemical identity. Once you're past the basics, look for human PK, dose-ranging, safety, liver markers, and objective body-composition data before drawing conclusions.
- 5-Amino-1MQ is investigated for NNMT inhibition and metabolic effects.
- It is not FDA-approved as a drug.
- 5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide.
- Proposed effects involve NNMT inhibition, NAD-related metabolism, adipose tissue biology, and energy expenditure.
- Its proposed mechanism is NNMT inhibition, affecting NAD/methylation metabolism and adipocyte energy handling. This is pharmacology, not peptide-receptor signaling. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Human efficacy is not established. Evidence is mostly animal/preclinical and community/body-composition discussion. Human efficacy and safety are not established for weight loss. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Standard Research Protocol [Research/Experimental]; Route: Oral capsule; Dose: Daily Dose: 50 mg – 100 mg; Frequency: Once daily (Morning); Timing: With or without food; Duration: 2 to 3 months; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Advanced/Performance Protocol [Community/Biohacker/Anecdotal]; Route: Oral capsule; Dose: 150 mg (Split doses); Frequency: 50 mg (3 times daily); Timing: 30 mins before meals/workout; Duration: 1 to 2 months; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Community oral use is reported, but dose claims are not clinical dosing. Interactions with methylation status and NAD pathways matter conceptually. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: not calculable.
- Half-life basis: Not a peptide; Routine human PK not established. This is an investigational small molecule, not a peptide.
- Beginner translation: this is a deliberately conservative read. A missing steady-state number does not mean the compound has no effect; It means the available human PK data are not strong enough to justify a precise accumulation estimate for common use patterns.
- Practical interpretation: Human pharmacokinetic data are limited or not established for routine therapeutic use.
- Peptide PK calculators do not apply. Oral absorption and small-molecule metabolism are the relevant concepts. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Stacks with GLP-1 drugs, NAD+, or fat-loss peptides are anecdotal and not validated.
- Often paired with NAD precursors, GLP-1s, exercise, or fat-loss stacks. Because it may intersect NAD/methylation pathways, avoid overloading with many metabolic modulators. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Unknown long-term safety, hepatic metabolism, drug interactions, pregnancy risk, and metabolic consequences are the default assumption until studied.
- Unknown human safety, liver/metabolic effects, methylation disturbance, and product quality are practical concerns. Do not imply safety from supplement-like oral format. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Weight, waist circumference, glucose, lipids, liver enzymes, renal function, and symptoms may be tracked in research contexts.
- Track weight/waist, glucose/lipids, liver enzymes, sleep/anxiety, and methylation-related symptoms if high-dose NAD/methyl donors are used concurrently. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- Not FDA-approved.
- Not a peptide.
- Athletes should treat non-approved metabolic agents as high-risk under S0 unless verified otherwise.
- 5-Amino-1MQ is not an FDA-approved weight-loss drug. It remains labeled non-peptide/RUO in the guide. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.